Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group

Andrea K. Ng, Joachim Yahalom, Jayant S. Goda, Louis S. Constine, Chelsea C. Pinnix, Chris R. Kelsey, Bradford Hoppe, Masahiko Oguchi, Chang-Ok Suh, Andrew Wirth, Shunan Qi, Andrew Davies, Craig H. Moskowitz, Siddhartha Laskar, Yexiong Li, Peter M. Mauch, Lena Specht, Timothy Illidge

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.

Original languageEnglish
Pages (from-to)652-669
Number of pages18
JournalInternational Journal of Radiation Oncology Biology Physics
Volume100
Issue number3
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Radiation Oncology
Lymphoma, Large B-Cell, Diffuse
refractories
radiation therapy
Lymphoma
Radiotherapy
Guidelines
radiation
chemotherapy
Dose Fractionation
Transplants
Recurrence
Drug Therapy
transplantation
dosage
stem cells
Stem Cell Transplantation
recommendations
fractionation
therapy

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Ng, Andrea K. ; Yahalom, Joachim ; Goda, Jayant S. ; Constine, Louis S. ; Pinnix, Chelsea C. ; Kelsey, Chris R. ; Hoppe, Bradford ; Oguchi, Masahiko ; Suh, Chang-Ok ; Wirth, Andrew ; Qi, Shunan ; Davies, Andrew ; Moskowitz, Craig H. ; Laskar, Siddhartha ; Li, Yexiong ; Mauch, Peter M. ; Specht, Lena ; Illidge, Timothy. / Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma : Guidelines from the International Lymphoma Radiation Oncology Group. In: International Journal of Radiation Oncology Biology Physics. 2018 ; Vol. 100, No. 3. pp. 652-669.
@article{2b4fb016ecf540a0a978baeeb66bd4d6,
title = "Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group",
abstract = "Approximately 30{\%} to 40{\%} of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.",
author = "Ng, {Andrea K.} and Joachim Yahalom and Goda, {Jayant S.} and Constine, {Louis S.} and Pinnix, {Chelsea C.} and Kelsey, {Chris R.} and Bradford Hoppe and Masahiko Oguchi and Chang-Ok Suh and Andrew Wirth and Shunan Qi and Andrew Davies and Moskowitz, {Craig H.} and Siddhartha Laskar and Yexiong Li and Mauch, {Peter M.} and Lena Specht and Timothy Illidge",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ijrobp.2017.12.005",
language = "English",
volume = "100",
pages = "652--669",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

Ng, AK, Yahalom, J, Goda, JS, Constine, LS, Pinnix, CC, Kelsey, CR, Hoppe, B, Oguchi, M, Suh, C-O, Wirth, A, Qi, S, Davies, A, Moskowitz, CH, Laskar, S, Li, Y, Mauch, PM, Specht, L & Illidge, T 2018, 'Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group', International Journal of Radiation Oncology Biology Physics, vol. 100, no. 3, pp. 652-669. https://doi.org/10.1016/j.ijrobp.2017.12.005

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma : Guidelines from the International Lymphoma Radiation Oncology Group. / Ng, Andrea K.; Yahalom, Joachim; Goda, Jayant S.; Constine, Louis S.; Pinnix, Chelsea C.; Kelsey, Chris R.; Hoppe, Bradford; Oguchi, Masahiko; Suh, Chang-Ok; Wirth, Andrew; Qi, Shunan; Davies, Andrew; Moskowitz, Craig H.; Laskar, Siddhartha; Li, Yexiong; Mauch, Peter M.; Specht, Lena; Illidge, Timothy.

In: International Journal of Radiation Oncology Biology Physics, Vol. 100, No. 3, 01.03.2018, p. 652-669.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

T2 - Guidelines from the International Lymphoma Radiation Oncology Group

AU - Ng, Andrea K.

AU - Yahalom, Joachim

AU - Goda, Jayant S.

AU - Constine, Louis S.

AU - Pinnix, Chelsea C.

AU - Kelsey, Chris R.

AU - Hoppe, Bradford

AU - Oguchi, Masahiko

AU - Suh, Chang-Ok

AU - Wirth, Andrew

AU - Qi, Shunan

AU - Davies, Andrew

AU - Moskowitz, Craig H.

AU - Laskar, Siddhartha

AU - Li, Yexiong

AU - Mauch, Peter M.

AU - Specht, Lena

AU - Illidge, Timothy

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.

AB - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will significantly benefit from high-dose therapy with autologous stem cell transplantation. The rationale for considering radiation therapy (RT) for selected patients with relapsed/refractory DLBCL as a part of the salvage program is based on data regarding the patterns of relapse and retrospective series showing improved local control and clinical outcomes for patients who received peritransplant RT. In transplant-ineligible patients, RT can provide effective palliation and, in selected cases, be administered with curative intent if the relapsed/refractory disease is localized. We have reviewed the indications for RT in the setting of relapsed/refractory DLBCL and provided recommendations regarding the optimal timing of RT, dose fractionation scheme, and treatment volume in the context of specific case scenarios.

UR - http://www.scopus.com/inward/record.url?scp=85044650018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044650018&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2017.12.005

DO - 10.1016/j.ijrobp.2017.12.005

M3 - Review article

C2 - 29413279

AN - SCOPUS:85044650018

VL - 100

SP - 652

EP - 669

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -